ELE-101
Phase 2Small molecule
ELE-101 is one of 36 small molecule programs targeting Depression. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
44 competitors in Depression
#DrugCompanyPhaseTrials
1Cymbalta
Jazz PharmaceuticalsApproved
Ketalar
AAultman Health Foundation
Approved
Brintellix
TakedaApproved
Zoloft
VViatris Specialty LLC
Approved
Vraylar
AbbVieApproved
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Wellbutrin
GGlaxo Dba Glaxosmithkline
Approved
Estrace
Novo NordiskApproved
Spravato
WWim Janssens
Approved
Mirapex
Boehringer IngelheimApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ELE-101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- EEleusis Therapeutics